A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
A phase 1/2 trial of JNJ-90014496 in non-hodgkin lymphoma, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05421663 by Janssen Research & Development, LLC, with 166 participants enrolled, started 2022-08-12 and due to reach its primary completion in 2041-07-30. Interventions recorded: JNJ-90014496. Conditions listed: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse. No results are recorded here; the registry entry is the source.
Setting
A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma
Phase
Phase 1/2
Sponsor
Janssen Research & Development, LLC
Registry
Enrolled
166